InsiderFlow

DNTH

Dianthus Therapeutics, Inc.$85.34+1.74 (+2.08%)
Prev Close$83.60·MCap$3.49B·P/E111.89·Vol387.3K·Yield

Buys (12M)

0

$0.00

Sells (12M)

11

$37.80M

Net Activity

Net Seller

$37.80M

Active Insiders

5

last 12 mo

Over the past 12 months, insider activity at Dianthus Therapeutics, Inc. (DNTH) has been exclusively selling, with 0 insider purchases totaling $0.00 and 11 insider sales totaling $37.80M. The most recent insider transaction was by Soteropoulos Paula (director), who sold $51.2K worth of shares on May 11, 2026. Dianthus Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $3.49B.

DNTH Insider Trading Activity

DateInsiderTypeValue
May 11, 2026 Soteropoulos PaulaSell$51.2K
Apr 10, 2026 Savitz RyanSell$738.8K
Apr 1, 2026 Soteropoulos PaulaSell$48.0K
Apr 1, 2026 Savitz RyanSell$9.49M
Mar 26, 2026 Soteropoulos PaulaSell$2.15M
Mar 13, 2026 CARR EDWARDSell$3.56M
Mar 13, 2026 Garcia MarinoSell$10.02M
Mar 13, 2026 Randhawa SimratSell$2.76M
Dec 4, 2025 Savitz RyanSell$903.6K
Nov 13, 2025 Randhawa SimratSell$7.38M0.5% OS
Sep 9, 2025 Savitz RyanSell$700.0K
Oct 3, 2023 Fairmount Funds Management LLCBuy$336.3K
Sep 28, 2023 Fairmount Funds Management LLCBuy$394.5K
Sep 25, 2023 Randhawa SimratBuy$52.8K
Sep 21, 2023 Fairmount Funds Management LLCBuy$396.0K
Sep 13, 2023 Fairmount Funds Management LLCBuy$271.7K
Feb 9, 2023 Third Rock Ventures IV, L.P.Sell$3.06M9.6% OS
Sep 20, 2021 Beetham Thomas W.Sell$41.1K
Sep 20, 2021 Deardorf CarenSell$42.0K
Sep 20, 2021 GARDNER JASONSell$96.5K
Sep 20, 2021 Nichols David WayneSell$38.3K
Sep 20, 2021 Stants KristenSell$38.6K

DNTH Insider Buying Activity

The following table shows recent insider purchases of Dianthus Therapeutics, Inc. (DNTH) stock reported via SEC Form 4 filings.

DateInsiderTypeValue
Oct 3, 2023 Fairmount Funds Management LLCBuy$336.3K
Sep 28, 2023 Fairmount Funds Management LLCBuy$394.5K
Sep 25, 2023 Randhawa SimratBuy$52.8K
Sep 21, 2023 Fairmount Funds Management LLCBuy$396.0K
Sep 13, 2023 Fairmount Funds Management LLCBuy$271.7K

DNTH Insider Selling Activity

The following table shows recent insider sales of Dianthus Therapeutics, Inc. (DNTH) stock reported via SEC Form 4 filings.

DateInsiderTypeValue
May 11, 2026 Soteropoulos PaulaSell$51.2K
Apr 10, 2026 Savitz RyanSell$738.8K
Apr 1, 2026 Soteropoulos PaulaSell$48.0K
Apr 1, 2026 Savitz RyanSell$9.49M
Mar 26, 2026 Soteropoulos PaulaSell$2.15M
Mar 13, 2026 CARR EDWARDSell$3.56M
Mar 13, 2026 Garcia MarinoSell$10.02M
Mar 13, 2026 Randhawa SimratSell$2.76M
Dec 4, 2025 Savitz RyanSell$903.6K
Nov 13, 2025 Randhawa SimratSell$7.38M0.5% OS
Sep 9, 2025 Savitz RyanSell$700.0K
Feb 9, 2023 Third Rock Ventures IV, L.P.Sell$3.06M9.6% OS
Sep 20, 2021 Beetham Thomas W.Sell$41.1K
Sep 20, 2021 Deardorf CarenSell$42.0K
Sep 20, 2021 GARDNER JASONSell$96.5K
Sep 20, 2021 Nichols David WayneSell$38.3K
Sep 20, 2021 Stants KristenSell$38.6K

DNTH Insiders

Soteropoulos Paula

director

Sold $2.25M
3 tradesLast: May 11, 2026
Savitz Ryan

officer: EVP, CFO & CBO

Sold $11.84M
4 tradesLast: Apr 10, 2026
Garcia Marino

director, officer: CEO AND PRESIDENT

Sold $10.02M
1 tradesLast: Mar 13, 2026
Randhawa Simrat

officer: EVP, Head of R&D

Bought $52.8KSold $10.14M
3 tradesLast: Mar 13, 2026
CARR EDWARD

officer: CHIEF ACCOUNTING OFFICER

Sold $3.56M
1 tradesLast: Mar 13, 2026
Fairmount Funds Management LLC

Director

Bought $1.40M
4 tradesLast: Oct 3, 2023
Third Rock Ventures IV, L.P.

10% Owner

Sold $3.06M
1 tradesLast: Feb 9, 2023
GARDNER JASON

See Remarks

Sold $96.5K
1 tradesLast: Sep 20, 2021
Stants Kristen

Chief People Officer

Sold $38.6K
1 tradesLast: Sep 20, 2021
Deardorf Caren

Chief Commercial Officer

Sold $42.0K
1 tradesLast: Sep 20, 2021
Beetham Thomas W.

See Remarks

Sold $41.1K
1 tradesLast: Sep 20, 2021
Nichols David Wayne

Chief Technical Officer

Sold $38.3K
1 tradesLast: Sep 20, 2021